[Somatostatin-like activity (SLI) in the blood during metformin treatment of obese patients with diabetes mellitus type 2].
Plasma somatostatin-like activity (SLI) was measured in obese women with type 2 diabetes in fasting condition and after a test meal (714 kcal: 27% carbohydrates, 8% protein, 73% fat). The tests were done twice: first, after a week of dietetic treatment and then 7 days of metformin administration, 1.5 g a day. Blood glucose and insulin concentration (IRI) were also followed throughout the test. The plasma SLI on fasting and after the test meal, before and after treatment with metformin did not show any significant differences. Blood glucose was lower in the fasting state significantly and serum insulin showed a tendency to decrease at the end of the test. These findings contradict the hypothesis of a possible role of somatostatin in peripheral blood in the enteric effect of metformin. The local (paracrine?) action of SLI secreted after metformin administration cannot be excluded.
Lawecki
J
J
Stryjek-Kamińska
D
D
Schusdziarra
V
V
D000328:Adult; D003920:Diabetes Mellitus / Q000097:blood*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D004435:Eating / Q000502:physiology; D005215:Fasting / Q000097:blood; D005260:Female; D006801:Humans; D008875:Middle Aged; D009765:Obesity; D013004:Somatostatin / Q000097:blood*
D013004:Somatostatin
Poziom aktywności somatostatynopodobnej (SLI) we krwi podczas leczenia metformina otyłych pacjentów z cukrzyca typu 2.